×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VRTX – vertex pharmaceuticals incorporated (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VRTX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/11
02:30 pm
vrtx
Sharp Rise in Senior Overdose Deaths Drives Launch of New Healthy Aging Video Program [Yahoo! Finance]
Low
Report
Sharp Rise in Senior Overdose Deaths Drives Launch of New Healthy Aging Video Program [Yahoo! Finance]
12/10
03:23 pm
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target raised by analysts at Wells Fargo & Company from $460.00 to $515.00. They now have an "overweight" rating on the stock.
Low
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target raised by analysts at Wells Fargo & Company from $460.00 to $515.00. They now have an "overweight" rating on the stock.
12/9
08:11 am
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Low
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
12/6
08:04 pm
vrtx
Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals? [Yahoo! Finance]
Medium
Report
Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals? [Yahoo! Finance]
12/6
07:01 am
vrtx
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
Medium
Report
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
12/5
10:04 am
vrtx
Vertex Pharmaceuticals (NASDAQ:VRTX) was given a new $564.00 price target on by analysts at Morgan Stanley.
Low
Report
Vertex Pharmaceuticals (NASDAQ:VRTX) was given a new $564.00 price target on by analysts at Morgan Stanley.
12/4
01:41 pm
vrtx
Why Analysts See Vertex Pharmaceuticals Story Shifting With New Pipeline Momentum and Valuation Debates [Yahoo! Finance]
Low
Report
Why Analysts See Vertex Pharmaceuticals Story Shifting With New Pipeline Momentum and Valuation Debates [Yahoo! Finance]
12/4
10:07 am
vrtx
Harding Loevner Global Equity's Views on Vertex Pharmaceuticals Incorporated (VRTX) [Yahoo! Finance]
Low
Report
Harding Loevner Global Equity's Views on Vertex Pharmaceuticals Incorporated (VRTX) [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/3/2025
04:02 pm
vrtx
vertex pharmaceuticals incorporated
BEAT
Report
-0.9%
vertex pharmaceuticals incorporated
8/4/2025
04:01 pm
vrtx
vertex pharmaceuticals incorporated
BEAT
Report
-20.6%
vertex pharmaceuticals incorporated
5/5/2025
04:01 pm
vrtx
vertex pharmaceuticals incorporated
BEAT
Report
-10.0%
vertex pharmaceuticals incorporated
2/10/2025
04:01 pm
vrtx
vertex pharmaceuticals incorporated
BEAT
Report
-3.1%
vertex pharmaceuticals incorporated
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/5
04:17 pm
vrtx
Form 4 VERTEX PHARMACEUTICALS For: Dec 03 Filed by: WAGNER CHARLES F JR
Low
Report
Form 4 VERTEX PHARMACEUTICALS For: Dec 03 Filed by: WAGNER CHARLES F JR
12/5
04:13 pm
vrtx
Form 4 VERTEX PHARMACEUTICALS For: Dec 03 Filed by: Tatsis Ourania
Low
Report
Form 4 VERTEX PHARMACEUTICALS For: Dec 03 Filed by: Tatsis Ourania
12/5
04:11 pm
vrtx
Form 4 VERTEX PHARMACEUTICALS For: Dec 03 Filed by: LEIDEN JEFFREY M
Low
Report
Form 4 VERTEX PHARMACEUTICALS For: Dec 03 Filed by: LEIDEN JEFFREY M
12/5
04:06 pm
vrtx
Form 4 VERTEX PHARMACEUTICALS For: Dec 03 Filed by: Biller Jonathan
Low
Report
Form 4 VERTEX PHARMACEUTICALS For: Dec 03 Filed by: Biller Jonathan
12/3
04:34 pm
vrtx
Form 144 VERTEX PHARMACEUTICALS Filed by: LEIDEN JEFFREY M
Low
Report
Form 144 VERTEX PHARMACEUTICALS Filed by: LEIDEN JEFFREY M
12/3
01:02 pm
vrtx
Form 144 VERTEX PHARMACEUTICALS Filed by: WAGNER CHARLES F JR
Low
Report
Form 144 VERTEX PHARMACEUTICALS Filed by: WAGNER CHARLES F JR
12/3
11:25 am
vrtx
Form 144 VERTEX PHARMACEUTICALS Filed by: WAGNER CHARLES F JR
Low
Report
Form 144 VERTEX PHARMACEUTICALS Filed by: WAGNER CHARLES F JR
12/3
11:00 am
vrtx
Form 144 VERTEX PHARMACEUTICALS Filed by: Tatsis Ourania
Low
Report
Form 144 VERTEX PHARMACEUTICALS Filed by: Tatsis Ourania
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/12
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
8.1%
4/1 Form 8-K VERTEX PHARMACEUTICALS For: Apr 01 7.7%
3/4 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $271.00 price target on the stock. 7.6%
7/31 Q2/2019 6/30/2019 EPS 1.260 ZacksConsensus 0.750 ActVsEst 0.510 - Beat 7.6%
3/2 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Argus from $248.00 to $270.00. They now have a "buy" rating on the stock. 5.1%
3/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at Piper Sandler. They now have a $300.00 price target on the stock. 5.0%
10/19 Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia 4.1%
10/21 Form 8-K VERTEX PHARMACEUTICALS For: Oct 21 4.1%
4/6 Form SEC STAFF LETTER VERTEX PHARMACEUTICALS 3.8%
4/15 Form 4 VERTEX PHARMACEUTICALS For: Apr 13 Filed by: Silva Paul M 3.7%
4/1 Form 8-K VERTEX PHARMACEUTICALS For: Apr 01 7.7%
3/4 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $271.00 price target on the stock. 7.6%
7/31 Q2/2019 6/30/2019 EPS 1.260 ZacksConsensus 0.750 ActVsEst 0.510 - Beat 7.6%
3/2 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Argus from $248.00 to $270.00. They now have a "buy" rating on the stock. 5.1%
3/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at Piper Sandler. They now have a $300.00 price target on the stock. 5.0%
10/19 Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia 4.1%
10/21 Form 8-K VERTEX PHARMACEUTICALS For: Oct 21 4.1%
4/6 Form SEC STAFF LETTER VERTEX PHARMACEUTICALS 3.8%
4/15 Form 4 VERTEX PHARMACEUTICALS For: Apr 13 Filed by: Silva Paul M 3.7%
TOP News Decliners
1/30
Vertex Pharmaceuticals Inc (VRTX) Q4 2019 Earnings Call Transcript [The Motley Fool]
-6.8%
4/7 The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response -6.2%
3/7 2 Biotech Stocks to Buy as Coronavirus Fears Tank the Market [The Motley Fool] -5.9%
4/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. -5.1%
3/17 Crispr: Beyond Gene-Editing [Seeking Alpha] -5.0%
4/21 Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients -4.4%
4/30 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at JMP Securities from $255.00 to $285.00. They now have a "market outperform" rating on the stock. -4.1%
2/26 Form 4 VERTEX PHARMACEUTICALS For: Feb 24 Filed by: WAGNER CHARLES F JR -3.8%
9/4 Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff [The Motley Fool] -3.7%
5/28 Form 4 VERTEX PHARMACEUTICALS For: May 24 Filed by: LEIDEN JEFFREY M -3.6%
4/7 The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response -6.2%
3/7 2 Biotech Stocks to Buy as Coronavirus Fears Tank the Market [The Motley Fool] -5.9%
4/28 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at Royal Bank of Canada from an "outperform" rating to a "sector perform" rating. -5.1%
3/17 Crispr: Beyond Gene-Editing [Seeking Alpha] -5.0%
4/21 Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients -4.4%
4/30 Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at JMP Securities from $255.00 to $285.00. They now have a "market outperform" rating on the stock. -4.1%
2/26 Form 4 VERTEX PHARMACEUTICALS For: Feb 24 Filed by: WAGNER CHARLES F JR -3.8%
9/4 Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff [The Motley Fool] -3.7%
5/28 Form 4 VERTEX PHARMACEUTICALS For: May 24 Filed by: LEIDEN JEFFREY M -3.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: